# Study of Natalizumab in Relapsed/Refractory Multiple Myeloma

> **NCT00675428** · PHASE1,PHASE2 · TERMINATED · sponsor: **Biogen** · enrollment: 6 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** BG00002 (natalizumab)

## Key facts

- **NCT ID:** NCT00675428
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-09
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Sponsor decision due to low enrollment and not safety concerns.
- **Last updated:** 2014-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00675428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00675428, "Study of Natalizumab in Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00675428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*